HEMATOLOGY

The FDA updated the prescribing label for the approval of ibrutinib to include efficacy and safety data as combination therapy with rituximab as treatment of patients with Waldenström’s macroglobulinemia.

The novel CD123-targeting antibody-drug conjugate IMGN632 demonstrated promising clinical activity in a cohort of heavily pretreated patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm and had a favorable tolerability.

Key opinion leaders close the discussion by providing insight into their respective protocols for acute graft-vs-host (GVHD) disease prophylaxis.

A discussion on upcoming clinical trial data presentations featured at the American Society of Hematology (ASH) 2020 Annual Meeting.

Deepu Madduri, MD, details the efficacy data from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma. 

Expert physicians consider how ongoing developments will impact the treatment paradigm of graft-vs-host disease.

Considerations regarding current clinical practice patterns for transplant-ineligible myeloma and the uptake of newer data by health care professionals.

Deepu Madduri, MD, details the efficacy data from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma. 

Key opinion leaders provide community oncologists with advice for implementing the REACH2 regimen to manage patients with acute graft-vs-host disease (GVHD).

A review of the favorable safety data from CARTITUDE-1 for relapsed/refractory multiple myeloma. 

A discussion on decision factors for switching to and deciding upon a second-line therapy, and an overview of the phase 3 REACH2 study with ruxolitinib for glucocorticoid-refractory acute graft-vs-host disease (GVHD).

Hematologist Rafael Fonseca comments on data demonstrated by the PEGASUS study in transplant-ineligible multiple myeloma and expectations for treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone vs other options moving forward.

Clinical updates from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma. 

Insight regarding the assessment of minimal residual disease in patients with multiple myeloma and using testing results to aid in treatment selection.

Key opinion leaders discuss treatment goals for frontline therapy in patients with acute graft-vs-host disease.

Rationale regarding the use of BCMA-targeted CAR T-cell therapy in relapsed/refractory multiple myeloma.

Expert physicians discuss the role and efficacy of JAK inhibitors in steroid-refractory graft-vs-host disease (GVHD).

Considerations for adding daratumumab to the combination of lenalidomide and dexamethasone to treat transplant-ineligible newly diagnosed multiple myeloma based on updated efficacy data from the phase 3 MAIA trial.

Mayo Clinic’s Rafael Fonseca, MD, comments on the benefits of newer therapies that are now available for patients with newly diagnosed transplant-ineligible multiple myeloma.

A discussion on the role on Janus kinase signaling in the pathogenesis of acute and chronic graft-vs-host disease (GVHD).

Deepu Madduri, MD, provides an overview of the treatment landscape for patients with triple-class refractory multiple myeloma.

Implications for assessing MRD status in patients with transplant-ineligible myeloma and treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone.

Recent updates from the ASH 2020 annual meeting on the phase 1b/2 CARTITUDE-1 trial for relapsed/refractory multiple myeloma.

Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.

Saad Usmani, MD, speculates on the current progress in treating multiple myeloma, while providing a glimpse into the future of cutting-edge treatments.